MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from offerings,
net
$837,526K
Proceeds from exercise of
stock options
$5,487K
Net cash provided by
financing activities
$843,013K
Increase (decrease) in
cash and cash...
$346,704K
Canceled cashflow
$496,309K
Proceeds from marketable
securities
$98,503K
Stock-based compensation
expense
$16,894K
Depreciation of property
plant and equipment
$587K
Deferred income tax
expense (recovery)
$447K
Non-cash operating lease
expense
$338K
Other receivables
-$205K
Other liabilities
$47K
Net cash provided by
(used in) investing...
-$407,282K
Net cash used in
operating activities
-$88,897K
Effect of exchange rate
changes on cash and cash...
-$130K
Canceled cashflow
$98,503K
Canceled cashflow
$18,518K
Purchases of marketable
securities
$505,652K
Net loss
-$102,302K
Purchases of property,
plant and equipment
$133K
Accounts payable and
accrued liabilities
-$1,801K
Prepaid expenses and
other current assets
$1,482K
Interest receivable and
accretion of discounts on...
$877K
Realized (gain) loss on
marketable securities
$400K
Operating lease liability
-$349K
Unrealized foreign
exchange (gain) loss
$204K
Back
Back
Cash Flow
logo_icon_teal_2280px-svg
Xenon Pharmaceuticals Inc. (XENE)
logo_icon_teal_2280px-svg
source: myfinsight.com
Xenon Pharmaceuticals Inc. (XENE)